NYSE · Healthcare · Biotechnology · USA
Veradermics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Veradermics is a biopharmaceutical company developing oral treatments for aesthetic and dermatological conditions. The company is developing VDPHL01, an extended-release oral formulation of minoxidil designed to treat progressive hair loss in men and women, and is conducting registration-directed clinical trials to support FDA approval applications.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Veradermics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on MANE yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.